Samuel Hou

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 89(Granted Patents)

Location History:

Neuchatel, CH (2015 - 2022)
La Chaux-de-Fonds, CH (2012 - 2024)

Company Filing History:

Glenmark Pharmaceuticals S.a.

Years Active: 2012-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12281169 - Antibodies that bind to OX40 and their uses (2025-04-21),

2. 12006367 - CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production (2024-06-11),

3. 11891454 - Production of T cell retargeting hetero-dimeric immunoglobulins (2024-02-06),

4. 11851502 - Production of T cell retargeting hetero-dimeric immunoglobulins (2023-12-26),

5. 11773166 - CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production (2023-10-03),

6. 11407839 - Antibodies that bind to OX40 and their uses (2022-08-09),

7. 11267891 - Fc variant antibodies and their uses (2022-03-08),

8. 10640564 - Antibodies that bind to CCR6 and their uses (2020-05-05),

9. 9493563 - Production of T cell retargeting hetero-dimeric immunoglobulins (2016-11-15),

10. 8975376 - Anti-alpha2 integrin antibodies and their uses (2015-03-10),

11. 8748585 - Antibodies that bind to OX40 and their uses (2014-06-10),

12. 8236315 - Humanized antibodies specific for von Willebrand factor (2012-08-07),

Title: Innovations and Contributions of Samuel Hou

Introduction

Samuel Hou is a notable inventor based in La Chaux-de-Fonds, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and immunoglobulins. With a total of 12 patents to his name, his work has the potential to impact therapeutic and diagnostic applications.

Latest Patents

One of Samuel Hou's latest patents is focused on antibodies that bind to OX40 and their uses. This invention relates to antagonist antibodies or fragments that specifically target human OX40, incorporating various heavy and light chain CDR sequences. Another significant patent involves CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production. This invention targets both the human CD3 and CD38 antigens, providing new avenues for therapeutic and diagnostic applications.

Career Highlights

Throughout his career, Samuel Hou has worked with prominent companies in the pharmaceutical and biotechnology sectors. He has been associated with Ichnos Sciences SA and Glenmark Pharmaceuticals SA, where he has contributed to innovative research and development projects.

Collaborations

Samuel has collaborated with notable professionals in his field, including Stanislas Blein and Darko Skegro. These collaborations have likely enhanced his research and development efforts, leading to impactful innovations.

Conclusion

Samuel Hou's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in therapeutic and diagnostic solutions.

This text is generated by artificial intelligence and may not be accurate.